Acquisition of Drug Royalty Corporation, by Cambridge Antibody Technology alerted the biomedical community to a potential form of cash revenue generation of which many had been largely unaware. This article considers the operation of drug royalty companies (DRCs), the type of deals the DRCs are striking with the biopharmaceutical industry, and the implications of these companies’ operations on drug licensing.